Optimization of an alum-anchored clinical HIV vaccine candidate.

"Competing interests D.J.I. and W.R.S. are named as inventors on a patent for pSer technology (US No. 11,224,648 B2). K.A.R. and D.J.I. are named as inventors on patent applications for an engineered pSer-conjugated SARS-CoV-2 RBD (PCT/US22/74309 and US No. 17/816,061). K.A.R. and D.J.I. are named as inventors on patent applications for the combination of alum and SMNP adjuvants (PCT/US2022/074302 and US No. 17/816,045). J.M.S. and W.R.S. are named as inventors on patent applications for MD39 trimers. K.A.R., W.R.S., and D.J.I. are named as inventors on patent applications for MD39_nohis8-pSer4 and MD39_nohis8_congly-pS4 (GGSGGGS) designs. The remaining authors declare no competing interests."

"We thank the Koch Institute Robert A. Swanson (1969) Biotechnology Center for technical support, specifically the Biopolymers and Proteomics, Flow Cytometry, and Animal Imaging and Preclinical Testing cores. Select figures created with BioRender.com. We acknowledge support from the NIH (the Koch Institute Core grant P30-CA14051 and UM1AI144462, AI161818, AI161297, AI125068, and P01AI048240 to D.J.I.) and the Ragon Institute of MGH, MIT, and Harvard. This material is based upon work supported in part by the U.S. Army Research Office through the Institute for Soldier Nanotechnologies at MIT, under Cooperative Agreement Number W911NF-18-2-0048. D.J.I. is an investigator at the Howard Hughes Medical Institute."